December 15, 2020 Press release - Non-regulatory Targovax ASA: Save the date – Capital Markets Day 2021
December 14, 2020 Press release - Regulatory Targovax ASA: Registration of share capital increase following exercise of options
December 10, 2020 Press release - Non-regulatory Targovax to present at DNB’s 11[th] Annual Nordic Healthcare Conference
December 8, 2020 Press release - Regulatory Targovax ASA: Exercise of options and resolution to increase the share capital
December 2, 2020 Press release - Non-regulatory Targovax ASA: Invitation to online presentation at 10:00 CET 2 December
December 1, 2020 Press release - Non-regulatory Targovax announces impressive objective responses as well as effects on non-injected lesions in ONCOS-102 trial in anti-PD1 refractory melanoma patients
November 24, 2020 Press release - Non-regulatory Targovax demonstrates encouraging survival data for ONCOS-102 in mesothelioma
November 17, 2020 Press release - Non-regulatory Targovax to present at Bryan Garnier & Co Virtual European Healthcare Conference
November 9, 2020 Press release - Non-regulatory Targovax announces poster at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2, 2020 Press release - Non-regulatory Targovax to present at the World Immunotherapy Congress
October 28, 2020 Press release - Non-regulatory Targovax announces formation of new Scientific Advisory Board
October 26, 2020 Press release - Non-regulatory Targovax ASA: Invitation to presentation of Targovax’s third quarter 2020 results, Thursday 5 November
October 22, 2020 Press release - Regulatory TARGOVAX ASA – REGISTRATION OF SHARE CAPITAL INCREASE FOLLOWING THE PRIVATE PLACEMENT
October 14, 2020 Press release - Regulatory TARGOVAX ASA – KEY INFORMATION RELATED TO THE SUBSEQUENT OFFERING
October 13, 2020 Press release - Non-regulatory Targovax announces that the ONCOS-102 and durvalumab trial successfully completes part 1 in colorectal cancer
October 12, 2020 Press release - Non-regulatory Targovax granted European Patent for ONCOS-102 in combination with checkpoint inhibitors
September 18, 2020 Press release - Regulatory Targovax ASA: Registration of share capital increase following settlement of restricted stock units
September 14, 2020 Press release - Non-regulatory Targovax is invited to present at H.C. Wainwright 22[nd] Annual Global Investment Conference
September 2, 2020 Press release - Non-regulatory Targovax is invited to present at Pareto Nordic Healthcare conference and RAS-targeted drug development summit
August 31, 2020 Press release - Regulatory Targovax ASA: Settlement of restricted stock units by primary insider and resolution to increase the share capital
August 12, 2020 Press release - Non-regulatory Targovax ASA: Invitation to presentation of Targovax’s second quarter and first half 2020 results, Thursday 20 August
June 29, 2020 Press release - Non-regulatory Targovax and Oblique enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms
June 24, 2020 Press release - Non-regulatory Targovax announces presentation of pre-clinical data from Next Generation ONCOS at AACR Virtual Annual Conference
June 23, 2020 Press release - Non-regulatory Targovax announces collaboration to evaluate ONCOS-102 in combination with KEYTRUDA® in mesothelioma
June 22, 2020 Press release - Non-regulatory Targovax to present at the upcoming 2020 Virtual European Biotech Investor Day 2020
June 22, 2020 Press release - Non-regulatory Targovax’s ONCOS-102 mesothelioma 12-month data powerfully demonstrate broad immune activation linked to clinical benefit
June 4, 2020 Press release - Non-regulatory Targovax enters collaboration with Leidos to add checkpoint inhibitor functionality to ONCOS viruses
May 14, 2020 Press release - Non-regulatory Targovax announces that the ONCOS-102 and durvalumab abstract is selected for a Poster Discussion Session at ASCO
May 6, 2020 Press release - Non-regulatory Targovax announces that abstract on interim phase I clinical data from the phase I/II peritoneal trial is accepted at ASCO
May 4, 2020 Press release - Non-regulatory Targovax releases update for mesothelioma trial combining ONCOS-102 and chemotherapy
April 30, 2020 Press release - Non-regulatory Targovax ASA appoints Dr Victor Levitsky as Chief Scientific Officer
April 30, 2020 Press release - Regulatory Targovax ASA: Issuance of restricted stock units (RSUs) to the board members
April 29, 2020 Press release - Non-regulatory Targovax ASA: Invitation to online presentation of Targovax’s first quarter 2020 results, Thursday 7 May
April 22, 2020 Press release - Non-regulatory Targovax and Valo Therapeutics enter collaboration to develop RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology
April 3, 2020 Press release - Non-regulatory Targovax ASA announces proposed new Chairman of the Board
March 30, 2020 Press release - Regulatory Targovax ASA: Registration of share capital increase following settlement of restricted stock units
March 26, 2020 Press release - Regulatory Targovax ASA: Settlement of restricted stock units and resolution to increase the share capital
March 26, 2020 Press release - Non-regulatory Targovax to present at the 2020 Solebury Trout Virtual Investor Conference today
March 23, 2020 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insiders in connection with settlement of RSUs
March 20, 2020 Press release - Non-regulatory Impact of corona virus (COVID-19) on Targovax’s operations
March 3, 2020 Press release - Non-regulatory Targovax announces completed enrollment in the ONCOS-102 trial in anti-PD1 refractory melanoma
March 3, 2020 Press release - Non-regulatory Targovax ASA: Invitation to presentation of Targovax’s fourth quarter 2019 results, Wednesday 11 March
January 28, 2020 Press release - Regulatory TARGOVAX ASA – REGISTRATION OF SHARE CAPITAL INCREASE FOLLOWING THE PRIVATE PLACEMENT
January 22, 2020 Press release - Regulatory TARGOVAX ASA – KEY INFORMATION RELATED TO THE SUBSEQUENT OFFERING
January 21, 2020 Press release - Non-regulatory Targovax announces encouraging data in mesothelioma study combining ONCOS-102 and standard of care chemotherapy
January 8, 2020 Press release - Non-regulatory Targovax and IOVaxis Therapeutics enters Option Agreement for TG mutant RAS vaccine license and clinical development in China
